<DOC>
	<DOCNO>NCT00309608</DOCNO>
	<brief_summary>The objective study test efficacy , safety tolerability several dos BI 1356 BS ( 1 , 5 , 10 mg take daily ) compare placebo give 12 week together metformin patient type 2 diabetes mellitus goal HbA1c level . In addition , unblinded treatment arm glimepiride add-on therapy metformin comparison . The influence several factor ( gender , age , weight , race , etc . ) bioavailability efficacy BI 1356 BS also test study .</brief_summary>
	<brief_title>Efficacy Safety BI 1356 BS ( Linagliptin ) Combination With Metformin Patients With type2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Inclusion_Criteria : Male female patient diagnosis type 2 diabetes mellitus previo usly treat metformin alone metformin one oral antidiabetic rug HbA1c 7.0 9.0 % screen patient treat metformin one oral antidiabetic drug HbA1c 7.5 10.0 % screen patient treated metformin alone HbA1c 7.5 10.0 % begin placebo runin phase Age &gt; 21 &lt; 75 year MI &gt; 25 &lt; 40 kg/m2 ( Body Mass Index ) Exclusion criterion : Exclusion_Criteria : Clinically relevant cardiovascular disease Impaired hepatic function Renal insufficiency impair renal function Treatment rosiglitazone pioglitazone within 6 month prior screen Treatment insulin within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>